All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2022-05-27.
From the record
Ardelyx, Inc.'s filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2022-05-27) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+32.8% a year over 9 filed years; profitable in 0 of 9.
From the record
Ardelyx, Inc.'s 9 filed years say what it did: revenue went from $42 million in fiscal 2017 to $407 million in fiscal 2025, up 32.8% a year; it rose in 7 of 8 years; the deepest fall was 94% from fiscal 2017 to fiscal 2018; net income was positive in 0 of 9 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 5.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Ardelyx, Inc.'s shareholder treatment is put at 5.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 43% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -37%: lost 37¢ per shareholder dollar. Leverage 67%: owes 67¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Ardelyx, Inc. lost about 37 cents for every dollar of shareholders' money, and gross profitability: its products earned about 73 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 67 cents per dollar of assets, and net share issuance: its share count grew 2.5% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 22% of 315 in its family; net margin -15.1%.
From the record
Ardelyx, Inc.'s standing among 315 graded names in its industry family: revenue of $407 million in fiscal 2025 ranks in the top 21% by size; a net margin of -15.1% ranks in the top 30%; revenue growth of 98.4% a year over the last 3 filed years ranks in the top 14% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 47% of 315 in its family for leadership; chief executive since 2014.
From the record
Ardelyx, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Raab, Michael (President & CEO, as filed), filing under that title since 2014-06-18, 12.4 years (top 10% of its family); the 20 officers and directors filing in the last fifteen months have been on the record a median of 3.5 years (bottom 19%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 20 people in charge now (top 49%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 46% of 273 in its family for room to expand.
From the record
Ardelyx, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $68 million against debt of $203 million leaves -26.9% of its assets as net cash, bottom 6% of its family; cash from operations less capital spending is -10.8% of revenue (top 33%); a gross margin of 90.3% (top 13%); research spending of 17.6% of revenue (bottom 22%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 16% of 306 in its family for growth drivers.
From the record
Ardelyx, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 98.4% a year over the last three filed years against 32.8% over all 9, speeding up (top 7% of its family); the newest year grew 22.1% (top 36%); research spending grew 26.7% a year (top 16%); capital spending grew 200.4% a year (top 3%) (its annual reports). Ardelyx, Inc. reported 5 product lines in fiscal 2025: Product IBSRELA at $274 million (67%), Product XPHOZAH at $104 million (25%), Product Supply Revenue at $16 million (4%), and 2 more; 4 of 5 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 40% of 233 in its family for expectations against reality.
From the record
Ardelyx, Inc.'s newest year against its own record: revenue of $407 million in fiscal 2025 came in 51.7% below the $843 million its prior three years' pace pointed to (bottom 18% of its family); net income of $62 million against a prior three-year average of $57 million (bottom 38%); a net margin of -15.1% against -64.6% before (top 37%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made